{"id":31262,"date":"2012-11-14T13:49:38","date_gmt":"2012-11-14T18:49:38","guid":{"rendered":"http:\/\/asweetlife.org\/?post_type=news&#038;p=31262"},"modified":"2015-12-30T05:00:23","modified_gmt":"2015-12-30T10:00:23","slug":"eu-approves-forxiga-for-treatment-of-type-2-diabetes-patients","status":"publish","type":"post","link":"https:\/\/asweetlife.org\/?p=31262","title":{"rendered":"EU Approves Forxiga for Treatment of Type 2 Diabetes Patients"},"content":{"rendered":"<p style=\"text-align: justify;\"><a href=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2012\/11\/Bristol-Myers-Logo-1.png\" rel=\"mfp\"><img decoding=\"async\" class=\"alignleft size-full wp-image-31263 lazyload\" title=\"Bristol-Myers Logo\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" data-src=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2012\/11\/Bristol-Myers-Logo-1.png\" alt=\"\" width=\"198\" height=\"160\" \/><\/a>The European Commission has approved\u00a0Bristol-Myers Squibb and AstraZeneca&#8217;s new type 2 diabetes therapy,\u00a0Forxiga\u00a0(dapagliflozin), for use in the European Union (EU).<\/p>\n<div style=\"text-align: justify;\">Forxiga\u00a0is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2) that works independently of insulin to help remove excess glucose from the body, a unique mode of action not seen in any other currently available treatments for type 2 diabetes. This is the first medicine in the new SGLT2 class to gain regulatory approval for the treatment of type 2 diabetes, a disease in which high unmet medical need exists.\u00a0<\/div>\n<div style=\"text-align: justify;\">\u00a0<\/div>\n<div style=\"text-align: justify;\">Forxiga\u00a0tablets are indicated as a once-daily oral medication to improve glycemic control in adult patients with type 2 diabetes.\u00a0Forxiga\u00a0is intended to be used as an adjunct to diet and exercise in combination with other glucose-lowering medicinal products, including insulin, or as a monotherapy in metformin-intolerant patients.\u00a0\u00a0<\/div>\n<p style=\"text-align: justify;\">Forxiga\u00a0works in the kidney to selectively inhibit SGLT2, resulting in the removal of excess glucose and its associated calories in the urine. Through the removal of excess glucose,\u00a0Forxiga\u00a0helps to reduce blood sugar levels. In clinical studies,\u00a0Forxiga\u00a0also showed reductions in weight and blood pressure. Bristol-Myers Squibb and AstraZeneca are currently seeking regulatory approval for\u00a0Forxiga\u00a0in several other countries.\u00a0<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The European Commission has approved Bristol-Myers Squibb and AstraZeneca&#8217;s new type 2 diabetes therapy, Forxiga (dapagliflozin), for use in the European Union (EU).<br \/>\nForxiga is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2) that works independently of insulin to help remove excess glucose from the body<\/p>\n","protected":false},"author":131,"featured_media":31263,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1442],"tags":[1576],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.9 (Yoast SEO v22.9) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>EU Approves Forxiga for Treatment of Type 2 Diabetes Patients<\/title>\n<meta name=\"description\" content=\"The European Commission has approved Bristol-Myers Squibb and AstraZeneca&#039;s new type 2 diabetes therapy, Forxiga (dapagliflozin), for use in the EU...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/asweetlife.org\/?p=31262\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ASweetLife Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/asweetlife.org\/?p=31262\",\"url\":\"https:\/\/asweetlife.org\/?p=31262\",\"name\":\"EU Approves Forxiga for Treatment of Type 2 Diabetes Patients\",\"isPartOf\":{\"@id\":\"https:\/\/asweetlife.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/asweetlife.org\/?p=31262#primaryimage\"},\"image\":{\"@id\":\"https:\/\/asweetlife.org\/?p=31262#primaryimage\"},\"thumbnailUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2012\/11\/Bristol-Myers-Logo-1.png\",\"datePublished\":\"2012-11-14T18:49:38+00:00\",\"dateModified\":\"2015-12-30T10:00:23+00:00\",\"author\":{\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\"},\"description\":\"The European Commission has approved Bristol-Myers Squibb and AstraZeneca's new type 2 diabetes therapy, Forxiga (dapagliflozin), for use in the EU...\",\"breadcrumb\":{\"@id\":\"https:\/\/asweetlife.org\/?p=31262#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/asweetlife.org\/?p=31262\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/?p=31262#primaryimage\",\"url\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2012\/11\/Bristol-Myers-Logo-1.png\",\"contentUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2012\/11\/Bristol-Myers-Logo-1.png\",\"width\":198,\"height\":160,\"caption\":\"Bristol-Myers Logo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/asweetlife.org\/?p=31262#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/asweetlife.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EU Approves Forxiga for Treatment of Type 2 Diabetes Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/asweetlife.org\/#website\",\"url\":\"https:\/\/asweetlife.org\/\",\"name\":\"ASweetLife\",\"description\":\"The Diabetes Magazine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/asweetlife.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\",\"name\":\"ASweetLife Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"caption\":\"ASweetLife Team\"},\"url\":\"https:\/\/asweetlife.org\/?author=131\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"EU Approves Forxiga for Treatment of Type 2 Diabetes Patients","description":"The European Commission has approved Bristol-Myers Squibb and AstraZeneca's new type 2 diabetes therapy, Forxiga (dapagliflozin), for use in the EU...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/asweetlife.org\/?p=31262","twitter_misc":{"Written by":"ASweetLife Team","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/asweetlife.org\/?p=31262","url":"https:\/\/asweetlife.org\/?p=31262","name":"EU Approves Forxiga for Treatment of Type 2 Diabetes Patients","isPartOf":{"@id":"https:\/\/asweetlife.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/asweetlife.org\/?p=31262#primaryimage"},"image":{"@id":"https:\/\/asweetlife.org\/?p=31262#primaryimage"},"thumbnailUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2012\/11\/Bristol-Myers-Logo-1.png","datePublished":"2012-11-14T18:49:38+00:00","dateModified":"2015-12-30T10:00:23+00:00","author":{"@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585"},"description":"The European Commission has approved Bristol-Myers Squibb and AstraZeneca's new type 2 diabetes therapy, Forxiga (dapagliflozin), for use in the EU...","breadcrumb":{"@id":"https:\/\/asweetlife.org\/?p=31262#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/asweetlife.org\/?p=31262"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/?p=31262#primaryimage","url":"https:\/\/asweetlife.org\/wp-content\/uploads\/2012\/11\/Bristol-Myers-Logo-1.png","contentUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2012\/11\/Bristol-Myers-Logo-1.png","width":198,"height":160,"caption":"Bristol-Myers Logo"},{"@type":"BreadcrumbList","@id":"https:\/\/asweetlife.org\/?p=31262#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/asweetlife.org\/"},{"@type":"ListItem","position":2,"name":"EU Approves Forxiga for Treatment of Type 2 Diabetes Patients"}]},{"@type":"WebSite","@id":"https:\/\/asweetlife.org\/#website","url":"https:\/\/asweetlife.org\/","name":"ASweetLife","description":"The Diabetes Magazine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/asweetlife.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585","name":"ASweetLife Team","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","caption":"ASweetLife Team"},"url":"https:\/\/asweetlife.org\/?author=131"}]}},"_links":{"self":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/31262"}],"collection":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31262"}],"version-history":[{"count":0,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/31262\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/media\/31263"}],"wp:attachment":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31262"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31262"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31262"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}